<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/73AA9C2B-B3B8-4C51-A07A-4C50B536CFBD"><gtr:id>73AA9C2B-B3B8-4C51-A07A-4C50B536CFBD</gtr:id><gtr:name>Ocera Therapeutics</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/73AA9C2B-B3B8-4C51-A07A-4C50B536CFBD"><gtr:id>73AA9C2B-B3B8-4C51-A07A-4C50B536CFBD</gtr:id><gtr:name>Ocera Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ECE19D2F-4E67-4E13-B76C-20FDDB3DC1B3"><gtr:id>ECE19D2F-4E67-4E13-B76C-20FDDB3DC1B3</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>Aubrey</gtr:otherNames><gtr:surname>Baigent</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D23967CC-4936-4B70-AF9A-D1488A7150BB"><gtr:id>D23967CC-4936-4B70-AF9A-D1488A7150BB</gtr:id><gtr:firstName>Rajeshwar</gtr:firstName><gtr:otherNames>Prosad</gtr:otherNames><gtr:surname>Mookerjee</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/620E6E8A-114C-48A6-BD89-337A18161B8C"><gtr:id>620E6E8A-114C-48A6-BD89-337A18161B8C</gtr:id><gtr:firstName>Nathan</gtr:firstName><gtr:otherNames>Alun</gtr:otherNames><gtr:surname>Davies</gtr:surname><gtr:orcidId>0000-0003-1625-9204</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BDAEC182-BBC5-40A6-9D45-F0228AE7D5A4"><gtr:id>BDAEC182-BBC5-40A6-9D45-F0228AE7D5A4</gtr:id><gtr:firstName>Rajiv</gtr:firstName><gtr:surname>Jalan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601448"><gtr:id>327D1DB0-1FF8-481E-8967-CD68D4C08805</gtr:id><gtr:title>Predictive utility of the dimethylarginines and ischemia modified albumin as prognostic markers in liver failure</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601448</gtr:grantReference><gtr:abstractText>When the liver fails, almost all the organs of the body are affected and they function inadequately. In patients that have existent liver disease, a relatively minor event such as intercurrent infection or bleeding can lead to catastrophic liver failure. This condition is referred to as acute on chronic liver failure. Our studies over the past 5 years have revealed that the current conventional tests that are performed to determine whether a patient with cirrhosis, who develop intercurrent problems, will progress to full blown liver failure are inadequate. A good test that could accurately identify patients at high risk of progressing to liver failure and mortality would allow early aggressive approach to treatment, transfer to specialist centres and listing for liver transplantation. Such a test is urgently needed. During studies determining why several organs fail to function during liver failure, we discovered two blood tests that may predict which ?at risk? patients would proceed to develop advanced liver failure and die. When these two tests were combined into a single scoring system, they were shown to correctly predict the outcome of about 90% of the 52 patients that were studied. We propose to perform a large study involving several important specialist centres in the UK to validate whether the test that we have developed is indeed useful. UCL has patented the test and a company developing an extracorporeal liver support device will co-fund the project. If the data are in keeping with those of the pilot experiments, it is possible that this test could reach the patients quickly and start to make a difference to their outcome.</gtr:abstractText><gtr:technicalSummary>Acute on chronic liver failure (ACLF) is a newly defined entity that encompasses patients with acute deterioration in liver function on the background of cirrhosis due to the effects of a defined precipitant that culminates in multiorgan dysfunction. ACLF is an important cause of mortality in patients with cirrhosis. If the end-organs and liver can be adequately supported, this condition has the potential for recovery. Evaluation of data from our prospective study over the past 5 years suggested that the currently used prognostic markers such as Child-Pugh, SOFA and MELD scores had poor sensitivity and specificity in predicting the outcome of these patients but pointed to the important role of inflammation from the pathophysiological perspective. Our studies focusing on the pathophysiologic basis of ACLF have suggested that superimposed inflammation on the background of cirrhosis increases the dimethylarginines (asymmetric and symmetric -ADMA/SDMA) by modulating the expression of their regulatory enzymes and further reduces albumin function. We therefore hypothesised that these may also serve as biomarkers to define outcome of patients with acute decompensation of cirrhosis. Pilot data: Following our initial studies in animals models of liver failure we included 52 patients with acute decompensation of cirrhosis and showed that DAS score (sum of ADMA+SDMA) and IMAR (Ischaemia Modified Albumin/Albumin concentration) predicted the risk of mortality (DAS:AUROC, 0.89), (IMAR:AUROC, 0.73) respectively. The combination of DAS score and IMAR (DAS+IMAR: DASIMAR) predicted outcome more accurately (AUROC: 0.92; sensitivity 92% and specificity 80%). The aims of the proposed study are to validate the role of DASIMAR as biomarkers in patients with acute decompensation of cirrhosis. The study has 2 primary endpoints: (a) to determine if the DASIMAR score is able to define which ?at-risk? patients progress to organ failure and (b) to determine the predictive utility of DASIMAR in defining mortality of patients that develop organ failure. Sequential blood samples and clinical data will be collected from 700 consecutive patients from 6 centres over a 2 year period. The data generated will be analysed using classical statistical modeling methods and also using novel mathematical tools. The proposed biomarkers have been patented by UCL and the Industrial partner, Vital Therapies Inc (USA) have committed to providing about 50% of the overall cost of the project.</gtr:technicalSummary><gtr:fund><gtr:end>2012-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>383029</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ocera Therapeutics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Drug Development</gtr:department><gtr:description>License agreement</gtr:description><gtr:id>C1C76364-33E3-4595-BFAC-2EF147A8A3B4</gtr:id><gtr:impact>Completion of GMP manufacture, Phase 1b and 2a studies. PK studies and dose finding.
Several disciplines and companies involved, Huntingdon Life sciences; AAI Pharma; UCSD Hepatology, USA;</gtr:impact><gtr:outcomeId>YUBxiVGFJMe-1</gtr:outcomeId><gtr:partnerContribution>potentially developing drug to market</gtr:partnerContribution><gtr:piContribution>Describing the early phase, first in man study, developing protocol, advising on design, etc.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS grant</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C520523D-A636-4C7B-99CF-C8D4492467E2</gtr:id><gtr:outcomeId>qcHqo1S5Cce0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>28000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>NIHR- Comprehensive Biomedical Research Centre New Initiative funding</gtr:description><gtr:end>2010-06-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>413CEB8E-EBB5-4C13-8280-350EA14F16F1</gtr:id><gtr:outcomeId>HFQFGcqsGhN0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Training Fellowship</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>26A43583-D080-428D-B588-6CCD9D6FE9B2</gtr:id><gtr:outcomeId>sdoQmyUnS780</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>91000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UKCLRN</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>387BE8DC-7AFE-43D2-9A8C-953389467360</gtr:id><gtr:outcomeId>QgZroT1RrNE0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>This discoveryprovides a means of identifying early in decompensation of chronic liver disease or acute liver failure, those patients that may benefit from early intervention such as liver support or escalation to listing for liver translplantation. The biomarker listed has 3 components that each identify different pathophysiological aspects key to identification of organ failure.</gtr:description><gtr:grantRef>G0601448</gtr:grantRef><gtr:id>E52FFD2F-CB63-4246-B7B9-A144B400500A</gtr:id><gtr:impact>The characterisation of patients used to inform the development of this discovery has highlighted a new syndrome in liver disease, acute-on-chronic liver failure, and this has now become a growing field of research with European and North American consortia set-up to specifically to address this condition.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>B2W12poJSwy</gtr:outcomeId><gtr:patentId>ZA200901432</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>a. Dimethylarginine score and Ischemia modified albumin as a prognostic biomarker in determining the outcome of liver failure.</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E17D8421-CA8F-4649-A0E3-4FDC84AF75CC</gtr:id><gtr:title>L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Gastrointestinal and liver physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/023313cbf99e0b35a64a858f9dccc5a1"><gtr:id>023313cbf99e0b35a64a858f9dccc5a1</gtr:id><gtr:otherNames>Kristiansen RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0193-1857</gtr:issn><gtr:outcomeId>546486658129f6.67319641</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0734BD58-3C25-455B-A71E-D40E3DAB6F40</gtr:id><gtr:title>Toward an improved definition of acute-on-chronic liver failure.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75428e17a51cde303245c0136f9ee38e"><gtr:id>75428e17a51cde303245c0136f9ee38e</gtr:id><gtr:otherNames>Jalan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>54648ad085a300.46498646</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>101C4BD4-858C-43F1-A739-88AABE780FD9</gtr:id><gtr:title>Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0844661b320898d02d3146750f2292d"><gtr:id>c0844661b320898d02d3146750f2292d</gtr:id><gtr:otherNames>Mehta G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>546486633ce3c8.87353031</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4505D33-A806-4B1C-8283-FA0C7DCDFDE8</gtr:id><gtr:title>Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75428e17a51cde303245c0136f9ee38e"><gtr:id>75428e17a51cde303245c0136f9ee38e</gtr:id><gtr:otherNames>Jalan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>54648ad0ac8748.90712177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A5343DE-F54C-42B9-96C1-FA0474626423</gtr:id><gtr:title>Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d401b9069e3f149e856ee361dc533fdc"><gtr:id>d401b9069e3f149e856ee361dc533fdc</gtr:id><gtr:otherNames>Mookerjee RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>ABgXKZDJMkx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51CE05F1-3973-4A56-A2B2-C640BF9610A1</gtr:id><gtr:title>Albumin infusion improves renal blood flow autoregulation in patients with acute decompensation of cirrhosis and acute kidney injury.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76aa1d842613891c7b16db5bbd5cc278"><gtr:id>76aa1d842613891c7b16db5bbd5cc278</gtr:id><gtr:otherNames>Garcia-Martinez R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>54648662bd3d93.84407806</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>256DE809-9EF8-4530-8371-FDA496FA1B11</gtr:id><gtr:title>Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d401b9069e3f149e856ee361dc533fdc"><gtr:id>d401b9069e3f149e856ee361dc533fdc</gtr:id><gtr:otherNames>Mookerjee RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>j8wEP7976Pu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB57D0B2-EA09-4595-9FC9-AC7FA7507DD9</gtr:id><gtr:title>Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d401b9069e3f149e856ee361dc533fdc"><gtr:id>d401b9069e3f149e856ee361dc533fdc</gtr:id><gtr:otherNames>Mookerjee RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>54648ad0d65de5.83537153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51551CD9-8C6E-4672-98ED-F5EBB25AF8EA</gtr:id><gtr:title>Renal dysfunction in cirrhosis is not just a vasomotor nephropathy.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebe0fbfc74a075ba19a07c4460d865a7"><gtr:id>ebe0fbfc74a075ba19a07c4460d865a7</gtr:id><gtr:otherNames>Adebayo D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>54648ad109d405.90158056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6243F807-FB29-4B41-8006-7B4DCCBAEB5C</gtr:id><gtr:title>Inflammation and portal hypertension - the undiscovered country.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0844661b320898d02d3146750f2292d"><gtr:id>c0844661b320898d02d3146750f2292d</gtr:id><gtr:otherNames>Mehta G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5464866312e394.86584348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4F0B5EE-B7D3-4D3C-9105-3662735F730E</gtr:id><gtr:title>Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75428e17a51cde303245c0136f9ee38e"><gtr:id>75428e17a51cde303245c0136f9ee38e</gtr:id><gtr:otherNames>Jalan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>mxTToo6u93k</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ED50C00-AD3F-4A89-A71E-4147EBD57E20</gtr:id><gtr:title>Liver: the gut is a key target of therapy in hepatic encephalopathy.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d38243c9291fca9c11a8d74cdb666ca6"><gtr:id>d38243c9291fca9c11a8d74cdb666ca6</gtr:id><gtr:otherNames>Sawhney R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1759-5045</gtr:issn><gtr:outcomeId>54648ad1326915.33085714</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DA35127-7E93-44F8-B872-B34608639A8D</gtr:id><gtr:title>Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75428e17a51cde303245c0136f9ee38e"><gtr:id>75428e17a51cde303245c0136f9ee38e</gtr:id><gtr:otherNames>Jalan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>54648662923464.29139929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA1B878D-96F8-4DDF-BEA8-32F7E662F7D0</gtr:id><gtr:title>Ammonia reduction with ornithine phenylacetate restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-ligated cirrhotic rats.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Gastrointestinal and liver physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8aea9f72de97539c97a456ce72e0f32b"><gtr:id>8aea9f72de97539c97a456ce72e0f32b</gtr:id><gtr:otherNames>Balasubramaniyan V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0193-1857</gtr:issn><gtr:outcomeId>NLZMtVMduDC</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601448</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>